KYMR241115P40000
- 0.00
- 0.000.00%
Kymera Therapeutics Newsroom
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Raises Target Price to $49
Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $49
Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $53
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Analysts Conflicted on These Healthcare Names: IQVIA Holdings (IQV), Halozyme (HALO) and Kymera Therapeutics (KYMR)
UBS Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $74
Kymera Therapeutics Is Maintained at Buy by UBS
Express News | Kymera Therapeutics Inc : UBS Cuts Target Price to $74 From $80
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report
Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript Summary
Kymera Therapeutics Analyst Ratings
Oppenheimer Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $56
Guggenheim Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $52
Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $56
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $53 to $60
Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...
Truist Trims Price Target on Kymera Therapeutics to $53 From $54, Keeps Buy Rating
Express News | Kymera Therapeutics Inc : Piper Sandler Cuts Target Price to $56 From $60
Kymera Therapeutics Shares Fall After Q3 Loss, Lower Revenue